Substance / Medication

Cefprozil

Overview

Active Ingredient
cefprozil
RxNorm CUI
19552

Indications

Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Streptococcus pyogenes Caused by. Streptococcus pyogenes NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication offr

Labeler: Physicians Total Care, Inc.Updated: 2010-12-08T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Cefprozil is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacokinetic and Bioequivalence Evaluation of Two Cefprozil Dispersible Tablets in Healthy Chinese Volunteers.
Xu Lang, Su Jianfen, Muhetaer Halimulati et al. · Clin Pharmacol Drug Dev · 2023
PMID: 37477442RCT
Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers.
Jia Fei-Fei, Tan Zhi-Rong, McLeod Howard L et al. · Xenobiotica · 2016
PMID: 26928207Trial
Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.
Nicolau David P, Sutherland Christina A, Arguedas Adriano et al. · Paediatr Drugs · 2007
PMID: 17407367Trial
Efficacy and tolerability assessment of cefprozil in children with acute otitis media.
Gupta Nomeeta, Bagga Vivek, Parmar Bharat J et al. · Indian J Pediatr · 2004
PMID: 15107512Trial
Pediatric tonsillopharyngitis--an evaluation of cefprozil in Indian patients.
Gupta Nomeeta, Mukherjee Abhijit, Moharana A K · Indian J Pediatr · 2004
PMID: 15280609Trial
[Multicenter, open clinical investigation on using cefprozil in therapy of otitis media in children].
Gryczyńska Danuta, Grzegorowski Michał, Hassman-Poznańska Elzbieta et al. · Otolaryngol Pol · 2003
PMID: 12741152Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefprozil (substance)
SNOMED CT
387538005
UMLS CUI
C0053882
RxNorm CUI
19552
Labeler
Physicians Total Care, Inc.

Clinical Data

This intervention maps to 12 entities in the Ltrl knowledge graph.

12
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.